Researchers develop materials for oral delivery of insulin medication

研究人员开发了用于口服胰岛素药物的材料

by New York University

来自 纽约大学

NYUAD's Research Scientist Farah Benyettou and Program Head of Chemistry Ali Trabolsi. Credit: NYU Abu Dhabi

NYUAD的研究科学家Farah Benyettou和化学项目负责人Ali Trabolsi。信用：纽约大学阿布扎比分校

A revolutionary technology developed within the Trabolsi Research Group at NYU Abu Dhabi (NYUAD) could dramatically improve the wellbeing of diabetic patients: an insulin oral delivery system that could replace traditional subcutaneous injections without the side effects caused by frequent injections.

纽约大学阿布扎比分校（Trabolsi Research Group）的Trabolsi研究小组开发的一项革命性技术可以显着改善糖尿病患者的健康状况：一种胰岛素口服给药系统可以代替传统的皮下注射，而不会出现频繁注射引起的副作用。

Using prepared layers of nanosheets with insulin loaded in between layers to protect it, the researchers developed gastro-resistant imine-linked-covalent organic framework nanoparticles (nCOFs) that exhibited insulin protection in the stomach as well in diabetic test subjects whose sugar levels completely returned to normal within two hours after swallowing the nanoparticles. Led by NYUAD's Research Scientist Farah Benyettou and Program Head of Chemistry Ali Trabolsi, the findings were published today in Chemical Science.

研究人员使用准备好的纳米片层和两层之间的胰岛素来保护它，从而开发出了耐胃酸的亚胺键合共价有机骨架纳米颗粒（nCOF），它们在胃中以及糖水平完全恢复的糖尿病测试对象中均表现出对胰岛素的保护作用。吞咽纳米颗粒后两个小时内恢复正常。在纽约大学研究科学家法拉·本雅图（Farah Benyettou）和化学项目负责人阿里·特拉博西（Ali Trabolsi）的带领下，这项发现今天发表在《化学科学》上。

Compared to the two FDA-approved technologies for the oral delivery of insulin, the system developed at NYUAD is biocompatible, highly stable in the stomach, specific, and able to deliver the right amount of insulin based on the diabetic subject's blood sugar levels. This treatment represents a step forward in treating this disease, which is the seventh leading cause of death worldwide.

与两种经FDA批准的口服胰岛素输送技术相比，NYUAD开发的系统具有生物相容性，在胃中高度稳定，具有特异性，并且能够根据糖尿病患者的血糖水平输送适量的胰岛素。这种治疗代表了该疾病的治疗方法的进步，该疾病是全球第七大主要死因。

"Our work overcomes insulin oral delivery barriers by using insulin-loaded nCOF nanoparticles which exhibit insulin protection in the stomach as well as a glucose-responsive release," said Benyettou. "This technology responds quickly to an elevation in blood sugar, but would promptly shut off to prevent insulin overdose and will dramatically improve the well-being of diabetic patients across the UAE and worldwide," she added.

Benyettou说：“我们的工作通过使用载有胰岛素的nCOF纳米颗粒克服了胰岛素口服传递障碍，该纳米颗粒在胃中表现出胰岛素保护作用以及对葡萄糖的响应释放。”她补充说：“这项技术对血糖升高迅速做出反应，但会迅速关闭以防止胰岛素过量，并将大大改善阿联酋乃至全世界的糖尿病患者的健康状况。”

NYUAD Research Scientist Farah Benyettou. Credit: NYU Abu Dhabi

NYUAD研究科学家Farah Benyettou。信用：纽约大学阿布扎比分校

点击：使用文档翻译功能

使用专业文献翻译功能

查看更多医学文章

免责声明：福昕翻译只充当翻译功能，此文内容及相关信息仅为传递更多信息之目的，仅代表作者个人观点，与本网站无关，版权归原始网站所有。仅供读者参考，并请自行核实相关内容。若需要浏览原文、下载参考文献等，请自行搜索文中提到的原文网站进行阅读。

来源于：phys